Sachin Tendulkar named brand ambassador for diabetes awareness campaign
Advertisement
Novo Nordisk, world’s leading diabetes care company has announced cricketing legend Sachin Tendulkar as the brand ambassador for ‘changing diabetes’, its programme in India to fight against the lifestyle disease.
The company officials announced Sachin as the ambassador at an event held in Hyderabad recently.
The announcement supports Novo Nordisk’s efforts focused on creating awareness about diabetes and its related complications.
Speaking on the occasion, Sachin said diabetes is a growing concern not just in India but the world over, and stressed the need for creating public awareness.
In India, 69.2 million people have diabetes and by 2035, this number is estimated to go up to 123.5 million. What is even more alarming is that 35 million people are unware that they have diabetes.
“With India having the world’s largest population of people with diabetes, at Novo Nordisk, our efforts have been focussed on raising awareness of diabetes and its impact on the lives of people affected by it, their families, society and eventually the country at large,” said Novo Nordisk India Pvt. Ltd vice president and general manager Melvin D’Souza.
The company officials announced Sachin as the ambassador at an event held in Hyderabad recently.
The announcement supports Novo Nordisk’s efforts focused on creating awareness about diabetes and its related complications.
Speaking on the occasion, Sachin said diabetes is a growing concern not just in India but the world over, and stressed the need for creating public awareness.
In India, 69.2 million people have diabetes and by 2035, this number is estimated to go up to 123.5 million. What is even more alarming is that 35 million people are unware that they have diabetes.
“With India having the world’s largest population of people with diabetes, at Novo Nordisk, our efforts have been focussed on raising awareness of diabetes and its impact on the lives of people affected by it, their families, society and eventually the country at large,” said Novo Nordisk India Pvt. Ltd vice president and general manager Melvin D’Souza.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.